NZ530056A - Single administration of 1.5 mg levonorgestrel increases compliance and decreases possibility of incorrect use of this post-coital contraceptive - Google Patents

Single administration of 1.5 mg levonorgestrel increases compliance and decreases possibility of incorrect use of this post-coital contraceptive

Info

Publication number
NZ530056A
NZ530056A NZ530056A NZ53005602A NZ530056A NZ 530056 A NZ530056 A NZ 530056A NZ 530056 A NZ530056 A NZ 530056A NZ 53005602 A NZ53005602 A NZ 53005602A NZ 530056 A NZ530056 A NZ 530056A
Authority
NZ
New Zealand
Prior art keywords
levonorgestrel
active ingredient
formulation
application dose
composition
Prior art date
Application number
NZ530056A
Other languages
English (en)
Inventor
Look Paul F A Van
Illesne Balogh
Katalin Komandi
Laszlo Nemes
Zsolt Szabo
Original Assignee
Richter Gedeon Vegyeszet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Vegyeszet filed Critical Richter Gedeon Vegyeszet
Publication of NZ530056A publication Critical patent/NZ530056A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16Masculine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
NZ530056A 2001-11-27 2002-11-26 Single administration of 1.5 mg levonorgestrel increases compliance and decreases possibility of incorrect use of this post-coital contraceptive NZ530056A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0105173A HU227198B1 (en) 2001-11-27 2001-11-27 Pharmaceutical composition for emergency contraception containing levonorgestrel
PCT/HU2002/000129 WO2003045397A1 (en) 2001-11-27 2002-11-26 Dosage regimen and pharmaceutical composition for emergency contraception

Publications (1)

Publication Number Publication Date
NZ530056A true NZ530056A (en) 2005-02-25

Family

ID=89998939

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ530056A NZ530056A (en) 2001-11-27 2002-11-26 Single administration of 1.5 mg levonorgestrel increases compliance and decreases possibility of incorrect use of this post-coital contraceptive

Country Status (33)

Country Link
US (1) US20050288264A2 (enExample)
EP (1) EP1448207B1 (enExample)
JP (1) JP2005516904A (enExample)
KR (1) KR100908161B1 (enExample)
CN (1) CN1551774A (enExample)
AP (1) AP1849A (enExample)
AT (1) ATE293978T1 (enExample)
AU (1) AU2002347401A1 (enExample)
BR (1) BR0210595A (enExample)
CA (1) CA2450359C (enExample)
DE (1) DE60203929T2 (enExample)
DK (1) DK1448207T3 (enExample)
EA (1) EA006545B1 (enExample)
EC (1) ECSP045171A (enExample)
ES (1) ES2239727T3 (enExample)
GE (1) GEP20063882B (enExample)
HR (1) HRP20040584B1 (enExample)
HU (1) HU227198B1 (enExample)
IL (1) IL159394A0 (enExample)
IS (1) IS2691B (enExample)
MA (1) MA27076A1 (enExample)
MX (1) MXPA04005104A (enExample)
NO (1) NO333984B1 (enExample)
NZ (1) NZ530056A (enExample)
OA (1) OA12730A (enExample)
PL (1) PL206010B1 (enExample)
PT (1) PT1448207E (enExample)
RS (1) RS50768B (enExample)
SI (1) SI1448207T1 (enExample)
TN (1) TNSN04048A1 (enExample)
UA (1) UA79942C2 (enExample)
WO (1) WO2003045397A1 (enExample)
ZA (1) ZA200404114B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2674776A1 (en) * 2006-12-20 2008-07-03 Duramed Pharmaceuticals, Inc. Orally disintegrating solid dosage forms comprising progestin and methods of making and use thereof
EA201070715A1 (ru) * 2007-12-20 2011-02-28 Тева Вимен'С Хелс, Инк. Режимы дозирования, фармацевтические композиции и упаковки для экстренной контрацепции
US8512745B2 (en) 2008-12-08 2013-08-20 Laboratoire Hra Pharma Ulipristal acetate tablets
EP2365811A1 (en) * 2008-12-12 2011-09-21 Laboratoire HRA Pharma A method for contraception
HRP20161437T1 (hr) 2009-04-14 2017-02-10 Laboratoire Hra Pharma Postupak hitne kontracepcije
NZ597239A (en) * 2009-06-23 2013-07-26 Bayer Pharma AG Pharmaceutical composition for emergency contraception
CN101732324B (zh) * 2009-12-31 2011-12-07 广州朗圣药业有限公司 一种含有左炔诺孕酮的紧急避孕药物组合物及其制备方法
AU2012264601C1 (en) 2011-06-01 2018-01-25 Estetra Srl Process for the production of estetrol intermediates
PT2714710T (pt) 2011-06-01 2016-07-12 Estetra Sprl Processo para a produção de intermediários de estetrol
EP2383279A1 (en) 2011-07-19 2011-11-02 Pantarhei Bioscience B.V. Process for the preparation of estetrol
HRP20170797T1 (hr) * 2011-08-11 2017-08-11 Estetra S.P.R.L. Primjena estetrola kao hitnog kontraceptiva
WO2014079840A1 (de) 2012-11-22 2014-05-30 Bayer Pharma Aktiengesellschaft Verwendung und anwendungsregime einer pharmazeutischen zusammensetzung enthaltend levonorgestrel und einen cox-inhibitor zur bedarfsweisen ("on-demand") kontrazeption
TN2015000511A1 (en) 2013-05-23 2017-04-06 Bayer Pharma AG Pharmaceutical composition and the use thereof, and application regime of said pharmaceutical composition for on-demand contraception
CN103877058A (zh) * 2014-03-26 2014-06-25 邵娜 一种左炔诺孕酮片及其制备工艺
MY195019A (en) 2015-06-18 2023-01-03 Estetra Sprl Orodispersible dosage unit containing an estetrol component
JP6866560B2 (ja) 2015-06-18 2021-04-28 エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ エステトロール成分を含有する口腔内崩壊性投与単位
MD3310346T2 (ro) 2015-06-18 2021-06-30 Estetra Sprl Comprimată orodispersabilă ce conține estetrol
HUE054589T2 (hu) 2015-06-18 2021-09-28 Estetra Sprl Szájban diszpergálódó esztetrol tartalmú tabletta
KR102712911B1 (ko) 2016-08-05 2024-10-04 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
CN110917154A (zh) * 2019-12-12 2020-03-27 上海信谊天平药业有限公司 一种左炔诺孕酮片的制备方法
TWI893101B (zh) 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
WO2022026901A2 (en) * 2020-07-30 2022-02-03 Acer Therapeutics Inc. Nk antagonists for contraception
CN119523923A (zh) * 2024-11-21 2025-02-28 华中药业股份有限公司 一种左炔诺孕酮片及其制备方法

Also Published As

Publication number Publication date
IS2691B (is) 2010-10-15
PL369520A1 (en) 2005-04-18
CA2450359C (en) 2011-05-10
US20050288264A2 (en) 2005-12-29
ATE293978T1 (de) 2005-05-15
GEP20063882B (en) 2006-07-25
RS4204A (sr) 2007-02-05
PT1448207E (pt) 2005-08-31
AP2004003046A0 (en) 2004-06-30
CN1551774A (zh) 2004-12-01
RS50768B (sr) 2010-08-31
MA27076A1 (fr) 2004-12-20
MXPA04005104A (es) 2004-08-19
IL159394A0 (en) 2004-06-01
IS7065A (is) 2003-12-05
HU227198B1 (en) 2010-10-28
JP2005516904A (ja) 2005-06-09
HUP0105173D0 (en) 2002-02-28
SI1448207T1 (en) 2005-10-31
PL206010B1 (pl) 2010-06-30
AU2002347401A1 (en) 2003-06-10
HRP20040584A2 (en) 2005-02-28
DE60203929D1 (de) 2005-06-02
TNSN04048A1 (en) 2006-06-01
HUP0105173A2 (hu) 2003-08-28
KR20040066088A (ko) 2004-07-23
BR0210595A (pt) 2004-06-08
ECSP045171A (es) 2004-08-27
EA200400731A1 (ru) 2004-12-30
DE60203929T2 (de) 2006-01-19
US20050032755A1 (en) 2005-02-10
KR100908161B1 (ko) 2009-07-16
ZA200404114B (en) 2005-10-26
NO333984B1 (no) 2013-11-04
UA79942C2 (en) 2007-08-10
EA006545B1 (ru) 2006-02-24
WO2003045397A1 (en) 2003-06-05
EP1448207B1 (en) 2005-04-27
DK1448207T3 (da) 2005-06-27
ES2239727T3 (es) 2005-10-01
HUP0105173A3 (en) 2004-03-29
CA2450359A1 (en) 2003-06-05
OA12730A (fr) 2006-06-28
AP1849A (en) 2008-05-23
HRP20040584B1 (en) 2012-11-30
EP1448207A1 (en) 2004-08-25
NO20041607L (no) 2004-04-20

Similar Documents

Publication Publication Date Title
CA2450359C (en) Dosage regimen and pharmaceutical composition for emergency contraception
CN102458386B (zh) 用于紧急避孕的药物组合物
KR100849919B1 (ko) 에스트로겐 대체 요법으로 치료중인 여성의 호르몬결핍증을 치료하기 위한 에스트로겐 및 안드로겐의 조합
JP2002509524A (ja) エストロゲン化合物とプロゲステロン様化合物よりなるホルモン組成物
JP2003048836A (ja) 効能を保持し無月経を引き起こす超低用量の経口避妊薬
AU747710B2 (en) Progestogen-antiprogestogen regimens
CN117715644A (zh) 纯孕激素口服避孕
HK1070275A (en) Dosage regimen and pharmaceutical composition for emergency contraception
KR20010110807A (ko) 조합 치료에서의 항프로게스타겐의 용도
HK1170686B (en) Pharmaceutical composition for emergency contraception
JP2007197459A (ja) 月経の出血を少なくし維持された効力を持つ超低投与量避妊薬

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 26 NOV 2022 BY DENNEMEYER + CO

Effective date: 20140822

EXPY Patent expired